Characteristics and Clinical Signifcance of Tumor Markers in Sera of Patients with Liver Carcinoma

Zhiyong Wu,R Chin
2006-01-01
Abstract:OBJECTIVE:To investigate the application of multi-tumor markers protein chip diagnose system in the analyzing, screening and monitoring of liver carcinoma. METHODS: The multi-tumor markers protein chip diagnose system to determine and analyze the levels of 12 tumor markers (NSE, CEA, AFP, CA_ 199 , CA_ 125 , CA_ 153 , CA_ 242 , f-PSA, HGH, Beta-HCG and FER) in sera of 120 liver carcinoma patients, 66 patients with liver diseases and 206 normal individuals. RESULTS: The positive rates of tumor markers in sera of patients with liver carcinoma [AFP (169.95±172.17 ng/mL),CA_ 125 (165.79±240.6335 ku/mL), CA_ 199 (105.22±160.41 ku/mL), CEA (16.88±24.98 ng/mL), CA_ 242 (50.52±70.72 ku/mL), NSE (14.67±59.07 ng/mL),CA_ 153 (28.70±36.01 ku/mL) and HGH (6.84±18.74 ng/mL)] were found higher than those of normal individuals, P=0.000, P= 0.000, P=0.000, P=0.000, P=0.000, P=0.01, P=0.000, P=0.000. The sensitivities were 72.5%, 50.0%, 57.5%, 53.3%, 40.0%, 13.3%, 26.7% and 15.0% respectively. The specialities were 96.6%, 94.7%, 94.2%, 91.3%, 96.1%, 99.0%, 90.8% and 95.1% respectively. The positive rates of tumor markers above targets besides NSE in sera of patients with liver carcinoma was significantly higher than those of patients with liver diseases. The highest positive rate of tumor marker AFP in serum of patients with liver carcinoma was 72.5%, and the sensitivity and speciality of combined other statistics targets, tumor markers in sera of patients with liver carcinoma achieved 94.2% and 70.9%, and compared with single target, there was a significantly difference, P=0.000. CONCLUSION: The combination of multi-tumor markers detrmined can raise screening rate of patients with liver carcinoma and can supply basis of comprehensive analysis for liver carcinoma.
What problem does this paper attempt to address?